MicuRx Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced on Friday that it has received Qualified Infectious Disease Product (QIDP) and Fast Track Designation from the US Food and Drug Administration (FDA) under the Generating Antibiotic Incentives Now (GAIN) Act, for contezolid (MRX-I) tablet and contezolid acefosamil (MRX-4) tablet and intravenous, as novel new oxazolidinone antibiotics intended for the treatment of moderate to severe diabetic foot infection (DFI) without concomitant osteomyelitis.
Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI. QIDP designation provides both products with a five-year extension of data exclusivity provisions and eligibility for Priority Review of its New Drug Application (NDA) for DFI once submitted. Both products were previously granted QIDP designation and Fast Track status in 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Dr Zhengyu Yuan, at MicuRx chief executive officer, said, 'We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection.'
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034